Lay Sciences' novel IgY technology is for treatment and prophylaxis
About us
-
LAY SCIENCES INC. LICENSED IGY RANGE OF PRODUCTS FROM
3
PARTNER COMPANIES:
Y PRODIGY BIOTECH
Y REAGENE BIOSCIENCES
Y KYNTOX BIOTECH
-
Plus years experience of each member in the Discovery Team
30
-
Headquartered in Florida, USA
Dr. SatishCEO
Chandran -
40
Countries launch planned
-
25
Indications targeted by various products developed with IgY platform
-
Lay Sciences Inc. completes development and launches ImmunIgY in select markets for Covid-19 www.myimmunigy.com
Q4'21
THE TECH
Targeted oral polyclonal IgY antibodies for therapeutics and prophylaxis
-
Oral dosing of IgY antibodies allows for therapeutic interventions and for prophylaxis in a targeted manner.
Y Targets that were previously considered undruggable.
-
Oral dosing avoids systemic exposure.
Y Thereby, reduces the unpleasant side effects and loss of efficacy
-
Proprietary formulations that protect IgY from gastric acids and proteases.
Y Allows for release of antibodies to targeted regions of the gut.
-
Antibodies are metabolized similarly as other ingested proteins.
Y Thereby, safe.
Strong Experience in Drug Discovery, Development and Commercialization
THE TEAM
-
Satish Chandran, Ph.D.
CEO and President
30+ years of Leadership Experience in Vaccines, Drugs, Biologics & Medical Devices
-
Uday Saxena, Ph.D.
30+ years of Leadership Experience in Drug Discovery
-
Chetan M. BANGERA
30+ years of Leadership Experience in Pharma Marketing - Innovators, Generics and Biologics
-
Gopi Kadiyala, Ph.D.
10+ years of experience in Diagnostic and IgY technology
CONTACT US
For suggestions & inquiries
4455 Military Trail, Suite 204,
Jupiter, FL 33458, USA
satish.chandran@laysciences.com
www.laysciences.com